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Abstract
Background: Research suggests that multidisciplinary genomic tumor boards (MGTB) can inform cancer patient
care, though little is known about factors influencing how MGTBs interpret genomic test results, make
recommendations, and perceive the utility of this approach. This study’s objective was to observe, describe, and
assess the establishment of the Breast Multidisciplinary Genomic Tumor Board, the first MGTB focused on
interpreting genomic test results for breast cancer patients with advanced disease.
Methods: We conducted a qualitative case study involving participant observation at monthly MGTB meetings
from October 2013 through November 2014 and interviews with 12 MGTB members. We analyzed social dynamics
and interactions within the MGTB regarding interpretation of genomic findings and participants’ views on
effectiveness of the MGTB in using genomics to inform patient care.
Results: Twenty-two physicians, physician-scientists, basic scientists, bioethicists, and allied care professionals
comprised the MGTB. The MGTB reviewed FoundationOne™ results for 40 metastatic breast cancer patients. Based
on findings, the board mostly recommended referring patients to clinical trials (34) and medical genetics (15), and
Food and Drug Administration-approved (FDA) breast cancer therapies (13). Though multidisciplinary,
recommendations were driven by medical oncologists. Interviewees described providing more precise care
recommendations and professional development as advantages and the limited actionability of genomic test
results as a challenge for the MGTB.
Conclusions: Findings suggest both feasibility and desirability of pooling professional expertise in genomically-guided
breast cancer care and challenges to institutionalizing a Breast MGTB, specifically in promoting interdisciplinary
contributions and managing limited actionability of genomic test results for patients with advanced disease.
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Background
Enthusiasm is increasing among oncologists for using
molecular tests to guide the application of targeted can-
cer therapies [1–3]. However, despite the rapid integra-
tion of genomic tests [4], care paths for using test results
to guide treatment do not yet exist. Given concerns
regarding insurance coverage and cost effectiveness of
genomic testing and uncertain ethical implications of
genomic information, establishing protocols for adminis-
tering and delivering genomic risk information to pa-
tients is important [2, 5, 6].
Previous studies suggest that interdisciplinary groups of
experts can inform genomically-guided patient care [7–9].
Cancer centers are establishing sequencing tumor boards
or multidisciplinary genomic tumor boards (MGTBs) to
review tumor sequencing results and identify potential
therapies for patients [10–14]. MGTBs are modeled after
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widely-practiced, disease-specific tumor boards comprised
of oncology, radiology, and pathology specialists who pool
their expertise to review newly-diagnosed and challenging
patients’ cases [15]. Research suggests that multidisciplin-
ary cancer care teams can improve patients’ therapy plan-
ning, pain control, and medication adherence, though
findings supporting their effectiveness in impacting pa-
tient survival and the costs of care are limited [16–18].
This may be due in part to discordance between recom-
mendations and patient values and lack of follow up on
tumor board recommendations [19, 20]. Nevertheless,
studies suggest that multidisciplinary tumor boards and
the use of standardized templates in tumor board confer-
ences can improve oncology patient outcomes based on
proxy measures such as the adherence to standards of care
and national guidelines for treatment [21, 22].
At this time little is known about the similarities and
differences in how traditional multidisciplinary tumor
boards and MGTBs impact patient care. What is known
is that an MGTB diverges from typical multidisciplinary
tumor boards by including professionals with expertise
in clinical or basic sciences relevant to genetics and genom-
ics, bioinformatics, and bioethics. For instance, The Mich-
igan Oncology Sequencing Project utilized a mock MGTB
to assess the clinical feasibility of implementing tumor se-
quencing to identify patients for biomarker-driven clinical
trials [10]. Investigators at The Moores Cancer Center re-
ported that their molecular tumor board involved partici-
pants from medical oncology, medical genetics, pathology,
bioinformatics, and basic and translational science who an-
alyzed patients with cancer diagnoses who had, on average,
three prior therapies [13]. They argued that for a heavily
pretreated population of patients with advanced disease,
genomic testing and a molecular tumor board’s recommen-
dations could optimize patient management, though lim-
ited access to targeted drugs and clinical trials pose a
hindrance [15]. Miller and colleagues found that physicians
were generally optimistic about the long-term potential for
genomic tumor analyses for metastatic cancer patients, but
more conservative about short-range benefits for patients
undergoing genomic sequencing today [14].
Limited information is available on factors influencing
how MGTBs interpret test results and make patient care
recommendations and members’ attitudes towards the
utility of this approach in guiding patient care. We re-
port on a qualitative study to observe, describe, and as-
sess the establishment of the Breast Multidisciplinary
Genomic Tumor Board, the first MGTB specifically fo-
cused on interpreting genomic test results for breast
cancer patients with advanced disease.
Methods
We conducted a 1-year qualitative case study employing
participant observation and in-depth interviews to study
the MGTB and its participants. The study was approved
by the University Hospitals Case Medical Center Institu-
tional Review Board. All individuals participating in
MGTB meetings in-person and via phone- or web-
conference signed informed consent documents indicat-
ing their voluntary participation in the study. Participant
observation was implemented at monthly meetings of
the MGTB from October 2013 through November 2014.
Participant observation refers to an approach in which
researchers are embedded in a social environment and
engaged in its ongoing activities to understand interactions
between individuals and meanings attached to experiences
and behavior [23, 24]. McGowan and Ponsaran took field
notes describing observations of each meeting, providing
us with an opportunity to observe the evolution of the
practices of the MGTB throughout the first year that it
met. All participants were invited to participate in an inter-
view about their involvement with the MGTB. After the
initial round of volunteers was secured, we sought breadth
in professional backgrounds to reduce the potential for
bias in the sample and to achieve theoretical saturation
[25]. The interview guide can be found in the Appendix.
Meeting proceedings and interviews were audio-recorded
for transcription and data analysis, which involved the-
matic analysis of qualitative text data and field notes [25].
We analyzed social dynamics and interactions within the
MGTB regarding interpretation and communication of
genomic findings and participants’ views on effectiveness
of the MGTB approach to incorporating genomic findings
into patient care, organizing the data into the themes of
MGTB practices, perceived benefits of the MGTB, and
perceived challenges of the MGTB.
Results
The MGTB was launched in October 2013 and met for
60–90 min each month. The MGTB was comprised of
26 individuals representing medical, surgical, and
radiation oncology, pathology, genetics, epidemiology,
biostatistics, bioinformatics, clinical chemistry, pharma-
cology, nursing, bioethics, patient advocacy, and patient
coordination. Interviews were conducted with 12 mem-
bers of the MGTB from medical oncology, radiation on-
cology, medical genetics, pathology, bioinformatics,
biostatistics, epidemiology, and patient coordination.
Figure 1 provides a description of the MGTB partici-
pants by area of specialization and whether they partici-
pated in only the participant observation component of
the study or both the participant observation and inter-
view components. Interviews ranged in length from 25
to 49 min. Observational data is presented below in nar-
rative form, and data drawn from the interviews is pri-
marily presented in block quotes, though data presented
on the practices of the MGTB were collected both
through observations and interviews. Given the small
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sample size, and to protect MGTB members’ identities,
we refer to interviewees as treating physicians,
physician-scientists, and basic scientists.
The goal of the MGTB was to provide a forum for on-
cologists to present cases of breast cancer patients who
had undergone FoundationOne™ testing1 to a multidiscip-
linary group of experts to aid in interpreting test results
and making patient care recommendations. Twenty six in-
dividuals participated in the MGTB during its first year,
though MGTB meetings typically involved five to 15 at-
tendees, including at least one medical oncologist, a path-
ologist, a bioethicist, and the patient navigator.
For each case, the physician ordering FoundationOne™
testing presented the patient’s medical history, the patholo-
gist showed and described the patient’s pathology slides,
and a discussion of the patient’s FoundationOne™ test
results followed. Results included individual genetic
markers that may be related to the patient’s cancer, variants
of unknown significance (VUS), and annotated explana-
tions supporting the relationship between each mutation or
genomic alteration and drug pathways. The MGTB dis-
cussed every marker reported by FoundationOne™ to make
recommendations regarding: 1) FDA-approved therapies
for breast cancer treatment; 2) therapies approved by the
FDA for use in other tumor types; and 3) clinical trials en-
rolling patients with genomic markers identified in the pa-
tient’s tumor. The MGTB discussed treatment and research
options and made recommendations for each genomic
marker by consensus. The MGTB established levels of evi-
dence for each recommendation based on Simon-Paik-
Hayes biomarker guidelines [26]. The meeting moderator
developed a web-based template to record, manage and re-
port recommendations to ordering physicians. Over the
course of the study, six treating physicians presented
their patients’ cases to the MGTB, and the board’s recom-
mendations became increasingly consistent and stream-
lined as participants became more familiar with the
patterns of reported in FoundationOne™ reports. System-
atizing the approach to reporting MGTB recommendations
for ordering clinicians was an important and deliberate goal
for establishing legitimacy, consistency and ethicality of the
MGTB, and may have influenced the treatment recommen-
dations of the MGTB in terms of ensuring consistent and
thorough review of FoundationOne™ reports.
Genomic testing and presentation to the MGTB was left
to physician discretion, however, all breast cancer patients’
cases sent by the hospital to Foundation Medicine for gen-
omic testing during the study period were presented at
the MGTB. Between October 2013 and November 2014,
the Breast MGTB reviewed cases of 40 female patients
with advanced metastatic breast cancer (Table 1). Ages
ranged from 34 to 77 (median age 54). Tumor types in
this population of breast cancer patients included 25
(63%) triple negative, 12 (30%) hormone receptor positive
(ER or PR ≥1%), and three (7%) HER2 overexpressed (see
Table 1). Patients reviewed by the Breast MGTB all had
advanced disease, in distinction to the standard breast
tumor board, where patients are almost exclusively pre-
sented at initial diagnosis so mostly have early stage
disease.
A basic scientist explained: “These [MGTB] patients
are the complicated ones. That’s why we’re sending them
out for genomics because we’re looking for other op-
tions, ‘cause we’re otherwise out of options.”
A treating physician explained that indications for under-
going genomic testing included progression on standard
breast cancer therapies (one for triple negative patients,
two for hormone receptor positive patients), and lobular
carcinomas with rare HER2 mutations with positive results.
The preponderance of triple negative cases reviewed by the
MGTB was explained by one treating physician in the
following way:
Fig. 1 MGTB participants by specialty
Table 1 Description of tumor types reviewed by MGTB, N = 40
Tumor Type Number Percent
Triple negative 25 63
Hormone receptor positive/HER2 negative 12 30
HER2 overexpressed 3 7
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“Unfortunately in that subgroup of women [triple nega-
tive patients], we still lack long-term sort of treatments
that help them in metastatic setting. So I probably, after a
couple of lines in metastatic setting for triple-negative
breast cancer, I think I would do the FoundationOne™ test-
ing for these patients.
This quote illustrates that the aggressive nature of
these tumors and the few standard treatment options
available to these patients makes FoundationOne™ test-
ing an appealing option for the triple negative patient
population.
FoundationOne™ reports included recommendations
for on-label and off-label drug therapies and clinical tri-
als that targeted genomic alterations in the patient’s
tumor. The MGTB made recommendations based on ac-
tionable findings: mutations with associated therapies or
clinical trials. The MGTB recommended referring most
patients to clinical trials enrolling individuals with their
genomic profile and clinical history (34, 85%) (see Table 2).
Phase I, II and III clinical trials were recommended when
available. The MGTB recommended FDA-approved ther-
apies for breast cancer for 13 (33%) patients. The MGTB
used FoundationOne™ results to recommend referring
more than a third of the patients to medical genetics (15,
38%) for evaluation of suspected germline abnormalities
associated with lifetime cancer risk. MGTB recommenda-
tions for additional testing were not always limited to rec-
ommendations presented in the FoundationOne™ report.
The MGTB reviewed the recommendations issued in the
commercial laboratory report, but made their own recom-
mendations based on the expert advice of the MGTB par-
ticipants. The group did not make recommendations for
drugs or clinical trials beyond those suggested in the com-
mercial laboratory report, but the MGTB occasionally made
recommendations for additional testing beyond the scope
of the FoundationOne™ recommendations, including andro-
gen receptor testing (5, 12%) for triple-negative patients
with a FoundationOne™ finding of a VUS suggesting an an-
drogen receptor mutation and confirmatory HER2 testing
for two patients (5%) for whom the patient’s chart, disease
progression, and/or FoundationOne™ HER2 mutation sta-
tuses were incongruent. The MGTB did not recommend
any off-label use of drug therapies approved by the FDA for
use in other tumor types. The organizers of the Breast
MGTB made a decision early on in establishing the group
that if there was insufficient data for FDA approval of
genomically-targeted agents for use in breast cancer that
the MGTB ought not recommend it for breast cancer pa-
tients outside of a clinical trial context.
A physician scientist described the tenor of recommenda-
tions made by the MGTB positively: “It’s very good. I think
Breast [MGTB] tends to be very conservative. After listen-
ing to just the general Genomic Tumor Board that we have
had here, and listening to other Tumor Boards, non-
genomic Tumor Boards, about … off-label use of different
drugs in other clinical settings, I think there are groups that
are a little bit more aggressive.”
MGTB participants were proud of the fact that they lim-
ited recommendations to standard lines of breast cancer
therapy, clinical trials, and referrals to medical genetics.
Treating physicians explained that the MGTB’s conserva-
tism in relation to recommending off-label use of FDA-
approved therapies reflected ethics of beneficence and non-
maleficence; they were uncomfortable recommending FDA-
approved drugs that might harm breast cancer patients
without proven benefit in their cancer type. The preponder-
ance of recommendations from the MGTB that patients
consider enrolling in targeted clinical trials reflected the lack
of FDA-approved drugs for treating breast cancer tumors
with specific genomic characteristics, and a recognition that
participation in clinical research holds potential for different
benefits, risks, and harms than standards lines of therapy.
Benefits
All interviewees described advantages of establishing the
MGTB, including providing more precise patient care rec-
ommendations and physician professional development.
Interviewees highlighted the importance of teamwork in
interpreting genomic data and making recommendations,
Table 2 Recommendations from MGTB, N = 40
Recommendation Number of Patients % Number of Patients who followed
MGTB recommendations
%
Genetics consultation 15 38 3 20
Clinical trial 34 85 6 18
FDA-approved therapies
• On-label 13 33 5 38
• Off-label 0 0 0 0
Additional testing/biopsy
• Androgen receptor testing 5 12 5 100
• Repeat HER2 testing 2 5 2 100
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and how this forum provided opportunities for interdis-
ciplinary discourse. A treating physician noted:
“The participation has been spectacular… We have the
cases presented and then have input from individuals
from clinical medicine, from basic science, from bio-
informatics and genomics about the testing …[T]he eth-
ics perspective… is critical as we delve into realms that
we don’t clearly understand, where we have limited in-
formation about certain findings and being able to…re-
sponsibly disclose that to the patient.”
Some physicians noted they would probably order
fewer genomic tests if they did not have the MGTB’s in-
terpretive support, and that the MGTB’s recommenda-
tions provided backing for the direction they were
planning to suggest for their patients.
Another benefit mentioned was professional education
through convening an MGTB:
“The ‘value added’ to the Genomic Tumor Board is
the other thing that probably doesn’t get discussed too
much is the overall ‘raising of the tides in the harbor,’ so
to speak, ‘raises all ships.’ … it’s a great forum to discuss
genomics and…serves as an educational forum, I think,
for all physicians.”
Along these lines, some basic scientists noted feeling re-
sponsible for drawing attention to matters of scientific rele-
vance in interpreting FoundationOne™ reports that may not
capture the attention of oncologists. As one explained:
“Some [clinicians] just don’t have the time and they…
don’t have probably even the training …to really under-
stand genomics in that sense, and so until clinicians are
trained in genomics … which I’m assuming will happen
years going forward … this is really proving to me that
you need a team of people to make this happen.”
Challenges
We observed and participants identified technical and eth-
ical challenges of incorporating genomic testing into pa-
tient care. For example, analysis of meeting and interview
transcripts revealed that though inherently multidisciplin-
ary, the MGTB’s discussions and recommendations were
largely driven by medical oncologists with occasional input
from basic scientists and physician-scientists. This dy-
namic remained constant during the 13 month time frame
of the study. Though the rhetoric of inclusion was univer-
sal in participants’ descriptions of the MGTB, it was pri-
marily treating physicians who conferred consensus of the
group’s recommendations. Interviewees noted that expert-
ise reflected in the recommendations was heavily influ-
enced by who participated in MGTB meetings. Several
called for increased substantive contributions from basic
and translational scientists, pharmacologists, and medical
geneticists to optimize the MGTB’s capacity, who were
specifically valued for their expertise in tumor biology,
interpreting genomic test results, referring patients to
specific clinical trials, and their understanding of disrupted
pathways that can predict response to FDA-approved
treatments. However, a basic scientist noted that the for-
mat of the FoundationOne™ reports limited scientists’ abil-
ity to contribute to the MGTB: “[W]e can’t take advantage
of expertise in bioinformatics because we’re not given any
information on the bioinformatics.”
The absence of regular representation from medical
genetics and genetic counseling was noted by several in-
terviewees as a crucial challenge for the MGTB; a genet-
ics professional participated in just one meeting during
the thirteen month observation period. One basic scien-
tist called for expanding the criteria for MGTB member-
ship, advocating for the inclusion of nurses and social
workers “because I think that patients will tell the nurses
and social workers things that they will not tell the doc-
tors. In fact I know they do.” However, the composition
of the group remained constant during the study period.
Disciplinary differences were apparent in how MGTB
members evaluated the quality of the FoundationOne™
test, yet participants’ concerns about the utility of the
test were rarely mentioned in the context of the MGTB
meetings. Treating physicians we interviewed focused on
how genomic testing is: “just one of the tools we have in
the toolbox. You don’t use every tool on every patient,
and not every doctor uses every tool.” A physician-
scientist explained: “In practice (and I don’t mean this
just here), I think [precision medicine] it’s still a little
ways away from really having a direct impact, I think a
lot of mutations that are screened for on those [Founda-
tionOne™ tests] are still not actionable clinically.”
Though this study did not systematically collect data on
how genomic test results informed ordering physicians’
recommendations for each patient’s care, treating physi-
cians we interviewed conveyed that the clinical utility of
genomic test results was low for many patients, and was
significant in impacting treatment course for a few (see
Table 2 for the number of patients whose course of
treatment was informed by MGTB recommendations).
As one treating physician explained:
When we get results that are useful, it can be very use-
ful and beneficial to the patient. But more often than
not, the results are of interest, potentially hypothesis-
generating, and have little impact, little clinical impact,
on the patient’s current state and seem to only benefit a
small proportion of our patients.
Clinicians struggled with how to strike an appropriate
balance of hope and realism regarding the actionability
of genomic test results, raising questions about the role
the MGTB should play in addressing the implications of
their recommendations for patient care.
In light of these limitations, the MGTB’s discussions
focused on what recommendations could be made with
the knowledge of patients’ treatment histories and the
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incomplete insight provided by genomic testing. Some
basic scientists noted that FoundationOne™ reports were
insufficiently detailed or too incomplete to assess the
value of these recommendations. While some were
confident in the accuracy of reports, others expressed
frustration that reports did not convey levels of confidence
in each recommendation, particularly for germline vari-
ants. A physician-scientist also questioned how Founda-
tion Medicine validates its product:
“They have teams of people to study the mutations, do
literature searches, figure out eligibility for clinical trials,
and so … we probably don’t rigorously question all they
put in their report as often as…we should. You know,
we pay them to do the test and assume that they’re
doing it correctly, but…I think that more validation is
what we need.”
The fact that the MGTB only reviewed patients with
advanced disease complicated the process of making rec-
ommendations, as FoundationOne™ reports regularly
identified FDA-approved therapies patients had already
exhausted and clinical trials with exclusionary enroll-
ment criteria. The tone of MGTB meetings suggested
that patients were committed to aggressively treating
their cancer, though occasionally a treating physician
would mention limitations the patient or her family had
put on the types of care they were willing to accept (e.g.,
chemotherapy via pill or infusion; aggressive vs. palliative
care; work, family, or insurance coverage considerations) or
willingness to travel to participate in a clinical trial. Never-
theless, in most cases the MGTB recommended shifting
away from standard therapies toward clinical trials. Foun-
dationOne™ reports clinical trials sites that are open nation-
ally and internationally, and at the time of this study few
were available in the city where patients were receiving
care. The MGTB typically looked to ClinicalTrials.gov, the
United States’ registry for public and private clinical studies
involving human subjects, for genomically-targeted oncol-
ogy clinical trials, but limited its recommendations to trials
with open sites in the region, recognizing that patients may
be most likely to consider participating in trials within driv-
ing distance.
Most interviewees mentioned they would like updates
on patients reviewed by the MGTB, to learn how treating
physicians and patients made use of recommendations,
and patient outcome data on genomically-targeted therap-
ies and clinical trials. A physician-scientist explained:
“I would like to see how many people were actually able
to…be on a clinical trial…to evaluate whether or not if
they were put on a different drug…it helped them or ex-
tended their life. I’d also like to know how they felt about
the whole experience, whether or not they thought it was
worthwhile, especially [because] it’s a lot of money.2 So
they’ve spent a lot of money on these things and so it
would be nice to know if they thought it was of benefit.”
Participants thought these data would help them as-
sess the utility of FoundationOne™ and the MGTB’s rec-
ommendations for informing patient care, though this
data was not reported back to the MGTB during the
study period.
Finally, not all participants considered FoundationOne™
ethically neutral. Specifically, participants wondered if pa-
tients understood they might receive unexpected or un-
wanted information, as genomic tumor analysis might
reveal germline mutations with implications for personal
and familial lifetime health risks. MGTB participants wor-
ried that if patients knew that tumor analyses could illu-
minate germline risks it may perpetuate mistrust and
misunderstanding of genetic testing. A physician-scientist
also wondered if more explicit informed consent processes
should be in place for sending prior tumor biopsies for
genomic testing to protect patient autonomy. A treating
physician stated:
“[There are] huge ethical issue[s] with many…social,
legal and other implications because of the cost, the po-
tential harm…I think we have to try and develop some
sort of controls around the situation by setting up guide-
lines in… a logical way…for [the] community, for all of
us, for the oncology world, because we’re all struggling
with it and it’s here right now…so we have to catch up.”
This statement suggests that MGTB members saw
themselves as trying to get in front of a deluge of gen-
omic testing that is rapidly making its way into clinical
oncology without requisite knowledge or procedures in
place to ensure well-informed, genomically-guided pa-
tient care. As a treating physician noted:
“We need more structure around the way we’re put-
ting together the recommendations, and the delivery of
the recommendations, because right now it’s still very
much… a work-in-progress where we’re trying to assess
what the level of evidence is to even make a certain rec-
ommendation…but we have not yet delved into how…
the treating oncologist actually delivers the information
and what kind of advice they should be giving and
exactly how we suggest that [information] be given.”
Discussion and conclusion
This paper reports on a case study of the establishment
of the first Breast MGTB. Findings suggest both feasibil-
ity and desirability of pooling professional expertise of
clinicians and scientists in reviewing and making recom-
mendations for genomically-guided breast cancer care.
This study also suggests that there are technical and eth-
ical challenges to institutionalizing a Breast MGTB.
This MGTB provides a unique forum to discuss gen-
omic test results for cancer patients. While the MGTB
resembles a regular multidisciplinary tumor board in its
use of a standardized template to issue recommenda-
tions to treating physicians based on national guidelines
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for evidence-based breast cancer treatment [21, 22], it
departs from a typical breast tumor board by involving
non-clinicians in interpreting commercial test results for
a single cancer type. A dynamic process unfolded in the
MGTB’s first operating year in which the interpretation
and standardization of recommendations continually
evolved. This case study confirms the feasibility of stand-
ardizing interdisciplinary evaluation and recommenda-
tions. This was especially evident in the MGTB’s uptake
of levels of evidence for making recommendations and re-
luctance to recommend FDA-approved therapies for off-
label use, which is consistent with the dominant epistemo-
logical frameworks in oncology of adherence to national
guidelines supporting evidence-based medicine and ran-
domized controlled trials [22, 27, 28] and the bioethical
principles of beneficence and nonmaleficence [29].
The Breast MGTB’s commitment to standardizing the in-
tegration of molecular tumor analyses into metastatic pa-
tient care signals what Nelson and colleagues characterize as
a new sociotechnical regime in oncology focused on action-
ability of genomic results, “whereby the articulation of mo-
lecular hypotheses and experimental therapeutics become
central to patient care,” through integration into existing
clinical practices, decision-making, clinical trials, and health
care infrastructures [30]. This case study confirms that mo-
lecular explanations inform the MGTB’s recommendations,
but perhaps not yet to the extent of constituting an action-
able regime. The MGTB primarily recommended referring
patients to clinical trials, yet several participants cautioned
that when patients had already exhausted standard therapies
their expectations needed to be tempered when approaching
genomic testing as an avenue for accessing new treatments
or clinical trials for which they would be eligible. This sug-
gests that FoundationOne™ testing is “actionable in
principle” more than in practice in that many tumor muta-
tions can be linked to FDA-approved therapies and/or clin-
ical trials [31], but access to targeted drugs and clinical trials
is still limited [15] and how MGTB recommendations im-
pact patient outcomes is as of yet unknown. Hence, clinical
utility is still largely promissory. This is evident in the levels
of evidence the MGTB assigned to recommendations based
on confidence in degree of actionability of results, and how
the MGTB limits clinically actionable results to drug targets
that are FDA-approved for breast cancer. The promissory
tenor of genomic testing is reflected in our findings that
treating physicians perceived the clinical utility of genomic
testing to be significant for few patients but low for most pa-
tients, which was further evidenced through the low uptake
of MGTB recommendations related to genomic testing by
patients whose cases were reviewed. While these findings
are consistent with previous research on follow up on tumor
board recommendations [15, 19, 20], our study cannot ex-
plain the specific factors that contributed to uptake of
MGTB recommendations by physicians and patients.
Another key finding included the widely-recognized im-
portance of a multidisciplinary team, with experts in sci-
ence, genomics, and ethics, which is aligned with the
makeup of other genomic tumor boards [13]. Yet, treating
physicians drove the Breast MGTB’s recommendations
during its first year, which may reflect modeling the MGTB
on a standard breast tumor board. To capitalize on the
MGTB’s multidisciplinary expertise, deliberate efforts may
be necessary to promote substantive contributions by clini-
cians and scientists unaccustomed to participating in tumor
boards. As Parker and colleagues have also suggested [15],
bolstering the attendance and engagement of professionals
from medical genetics and pharmacology are especially
warranted to increase substantive expertise and under-
standing of genetics and drug pathways. The potential for
dependence on commercial laboratory interpretation of test
results poses a problem for the rapid integration of
un(der)-validated genomic tests, posing risks to the integ-
rity of clinical judgment and patient care [5]. This may be
especially important if the MGTB is to avoid overreliance
on the commercial laboratory’s interpretation of genomic
test results, a concern raised both by physician-scientists
and basic scientists who noted the group’s relatively uncrit-
ical acceptance of the validity of (FoundationOneTM) re-
sults. Participants also noted benefits of increasing the
participation of professionals who may be particularly use-
ful for securing informed consent for genomic testing,
managing incidental germline findings, and serving as edu-
cational resources for MGTB members [32].
Finally, all interviewees described benefits of conven-
ing the MGTB for patients and especially physicians,
with one participant referencing the aphorism “a rising
tide lifts all boats” to signify the communal benefits of
pooling expertise to enhance genomic knowledge. While
the stated goal of the MGTB was to improve patient
care through targeted therapeutics, an underlying, and
increasingly prominent, goal became educating clinicians
about genomic markers, drug pathways, and the inter-
pretation genomic test results. These goals do not negate
one another, but occur in parallel, sometimes complemen-
tarily but with potential for conflict. This finding reflects
the current state of genomic medicine, with its technical
limitations and the unknown potential for impacting pa-
tient outcomes, but also raises the importance of acknow-
ledging how the MGTB can be of use to physicians and
patients considering testing. Of interest is how the MGTB
can balance responsible stewardship of genomic technol-
ogy in promoting cancer patients’ autonomous decision-
making and professional education on incorporating gen-
omics into clinical practice with a holistic understanding
of the benefits and limitations of technology. Adequate in-
formed consent poses a significant challenge to integrating
genomic tools into oncology for two reasons. First, low
genetic literacy can influence patients’ comprehension of
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the differential implications of germline and somatic test-
ing [2]. Second, most oncologists have minimal training
and confidence in genomic testing and interpretation of
results [2, 33, 34]. Thus, in addition to promoting genomic
expertise among oncologists through professional educa-
tion [15], an MGTB is well-positioned to promote better
informed consent through educating both physicians and
their patients. Previous research has suggested that involv-
ing patients in multidisciplinary tumor board meetings de-
serves further consideration as an avenue for ensuring that
tumor board recommendations reflect patient values [20].
This may be one pathway to both educate metastatic breast
cancer patients about what genomic testing can realistically
offer, and to assess how patient values can inform MGTB
deliberations regarding recommendations for treatment.
This study has three primary limitations. Our analysis is
limited to a single MGTB and reflects the dynamics at one
institution; there may be local variability in the approaches
and implementation of MGTBs. Furthermore, this study
did not systematically track patient outcomes; a clinical re-
port presenting information about patients presented at the
MGTB will be published separately. Finally, this study did
not gather the perspectives of patients who were offered
FoundationOne™ testing. Patient viewpoints and the factors
that contributed to their decisions to undergo testing and
engage MGTB recommendations are unknown.
This case study presents several directions for future re-
search, including assessment of professional variability in of-
fering genomic testing in oncology and making treatment
recommendations on the basis of genomic findings, and
how physicians communicate the risks and benefits of gen-
omic testing and respond to MGTB recommendations. Fac-
tors that influence patients’ decisions to undergo or forego
genomic testing and their responsiveness to MGTB recom-
mendations also warrant attention. Finally, this study raises
questions about broader ethical and social implications of
offering genomic testing to advanced breast cancer patients
with the aim of improving treatment options, but more
often than not, presenting opportunities to participate in
clinical trials research. Engagement with these issues will
provide a more holistic understanding of the ethical and so-
cial implications of the clinical integration of genomic tech-
nology in oncology.
Endnotes
1Described by the commercial vendor as “a fully in-
formative genomic profile that helps physicians make
treatment decisions for patients with cancer by identify-
ing the molecular growth drivers of their cancers and
helping oncologists match them with relevant targeted
therapeutic options”[35]




Impressions of involvement in the MGTB
1. What is your professional role on the
Multidisciplinary Genomic Tumor Board (MGTB)?
2. Now that the MGTB has been meeting for several
months, what is your impression of your experience
thus far?
a. What has been going well?
b. What areas require improvement?
c. How well represented are various disciplinary
perspectives in MGTB deliberations?
i. Are there particular perspectives that you
have found especially helpful or interesting?
ii. From which disciplines would you like to hear
more?
3. What do you think of the presentations of cases
and (FoundationOneTM) reports?
a. How useful is it to receive the
(FoundationOneTM) reports before the meeting?
b. What do you think of the format of the MGTB
meetings? (proceeding from clinical history of
patient to (FoundationOneTM) report to action
plan)?
4. What do you see as the benefits of convening the
MGTB?
5. Conversely, what do you see as the drawbacks of
having an MGTB analyze and make recommendations
regarding patient care?
6. In the course of the MGTB meetings, the participants
have also weighed in on (a commercial platform).
What are your impressions of the process of
developing (a commercial platform)? What impact do
you think the platform will have on clinical care once
implemented?
Determining Clinical Utility
7. Would you please describe how
(FoundationOneTM) reports patient results?
a. In your opinion, what factors influence the
MGTB s interpretation of (FoundationOneTM)
reports?
b. In your opinion, are there any changes you
would suggest for how patient results are
reported?
8. How does the MGTB make recommendations
regarding therapeutic options and clinical trials?
a. If it were up to you as an individual, would you
have made the same recommendations that the
MGTB has thus far? Why or why not?
b. In your opinion, how does clinical utility factor
into the recommendations that are made?
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c. What are the most important criteria for deciding
that genomic data might have clinical utility?
When you make a decision, what considerations
are most important?
9. How would you describe the process for making a
recommendation? What are your impressions?
a. Are there cases that have been presented that
stood out to you as unique or noteworthy? What
make them stand out to you? (e.g. straightforward,
ambiguous)
Use of MGTB recommendations
10.Are you a clinician who orders (FoundationOneTM)
tests for breast cancer patients?
a. If yes, how useful are the MGTB s
recommendations regarding (FoundationOneTM)
test results? How do you communicate
(FoundationOneTM) results and MGTB
recommendations to your patients? How receptive
have patients been to recommendations?
b. If no, what would you like to know about how
these recommendations are utilized by clinicians
and how results are conveyed to and received by
patients?
11.Are (FoundationOneTM) reports and corresponding
MGTB recommendations making their way into the
electronic medical record?
a. What do you see as the implications of including
these results in the electronic medical record?
Or, of leaving them out?
Going Forward
12.What role do you think the MGTB should have in
the future?
a. How should it be organized?
b. Who should be involved?
c. Should it expand its scope beyond reviewing
(FoundationOneTM) test results for breast cancer
patients? Why or why not?
13.What do you see as the most pressing ethical, legal
and social implications of sequencing tumors of
breast cancer patients?
a. How, if at all, do you think that the MGTB can
mediate these challenges in the future?
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